Strategic Focus BioTissue has divested non-ocular surgical assets to concentrate exclusively on ocular care, presenting a clean growth runway for eye care product lines and related regenerative therapies.

Product Leadership With CAM360 AmnioGraft, Prokera, AmnioGraft, and AmnioGuard powered by CryoTek technology, BioTissue offers FDA-recognized anti-inflammatory, anti-scarring, and anti-angiogenesis capabilities, signaling strong differentiators for ophthalmology purchasing committees.

Clinical Footprint Over one million implants performed and a robust 440 peer‑reviewed publications highlight evidence-based outcomes, supporting compelling value propositions for clinicians and hospital networks seeking proven regenerative solutions.

Market Positioning Recent leadership additions and industry recognition, including a spot on Fortune Best Workplaces in BioPharma, bolster credibility when engaging with large ophthalmology groups, academic centers, and distributors.

Partnerships & Expansion Strategic relationships such as LifeLink Tissue Bank collaboration and ongoing board & advisory enhancements open doors for co-developed programs, distribution opportunities, and expanded access in hospital systems and specialty clinics.